Compare · NVO vs VIRX
NVO vs VIRX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Viracta Therapeutics Inc. (VIRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and VIRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 2125.7x VIRX ($89.9M).
- Over the past year, NVO is down 45.6% and VIRX is up 0.0% - VIRX leads by 45.6 points.
- NVO has hit the wire 8 times in the past 4 weeks while VIRX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 2 for VIRX).
- Company
- Novo Nordisk A/S
- Viracta Therapeutics Inc.
- Price
- $42.79+1.42%
- $0.07-54.31%
- Market cap
- $191.15B
- $89.9M
- 1M return
- -7.76%
- +0.00%
- 1Y return
- -45.65%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Viracta Therapeutics Inc.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest VIRX
- Viracta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Viracta Therapeutics Announces Wind Down of Operations
- Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Viracta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits
- Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Viracta Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Other Events, Financial Statements and Exhibits
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
- Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 839,741 units (SEC Form 4)
- Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 126,478 units (SEC Form 4)